北京若生智能科技有限公司
Drug Database
HO

hormone patches (Lyrelle / Lyrelle 50 / Lyrelle 80)

✓ Approved

Shire · ESR1 · 小分子

什么是 hormone patches？

hormone patches 是一种小分子，由Shire研发。该药已获批，用于治疗相关适应症，给药途径：Transdermal。

药物档案

商品名Lyrelle, Lyrelle 50, Lyrelle 80
公司Shire
药物类别小分子
分子靶点ESR1, PGR
给药途径Transdermal
状态Approved
来源： ClinicalTrials.gov, Shire

作用机制

分子靶点

hormone patches 作用于 2 个分子靶点：

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

hormone patches 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresHormone replacement therapy✓ Approved

相关研究文献

PubMedThe Analyst2026-10-26

Agricultural waste-derived sweat sensor integrated into wettability-tunable microfluidics for noninvasive metabolic evaluation.

Guo Shuyi S, Wang Haixu H, Bo Xiangjie X

Wearable sweat patches allow real-time and noninvasive monitoring of metabolism through sweat biomarker analysis. However, challenges related to sweat collection efficiency and the lack of sustainable sweat sensors impede the widespread adoption of sweat analysis. Here, we report the design of a wearable sweat patch integrating an agricultural waste-derived sweat sensor for sensitive sweat uric acid (UA) and glucose (Glu) analysis and surface wettability-controlled microfluidics for efficient sweat collection. We evaluate the performance of the wearable patch for the noninvasive monitoring of UA and Glu in sweat. We also validate the usability of the wearable patch in assessing metabolic status in metabolic disorders including gout and diabetes.

PMID 42929105
阅读全文 →
PubMedJournal of applied biomaterials & functional materials2026-10-26

Arbutin/kojic acid-loaded MHA hydrogel array patches attenuate UVB-induced epidermal hyperplasia and remodeling-associated responses.

Lee Seung-Min SM, Cha Sangryul S, Jeon DooLee D, Choi Wooseok W et al.

Acute ultraviolet B (UVB) exposure induces epidermal hyperplasia, pigmentation-related responses, and early extracellular matrix remodeling. Topical tyrosinase inhibitors, including arbutin and kojic acid, can have limited residence on damaged skin. Here, we evaluated a skin-conformal composite patch comprising aligned polyurethane nanofiber membranes integrated with methacrylated hyaluronic acid (MHA) hydrogel arrays loaded with arbutin or kojic acid. Seven-week-old Hairless Mouse, Strain 2 (HRM2) mice were assigned to six groups: control (CTL), UVB only (UV), UVB plus topical arbutin (UVA), UVB plus topical kojic acid (UVK), UVB plus arbutin-loaded MHA patch (UV-A-MHA), and UVB plus kojic acid-loaded MHA patch (UV-K-MHA). Dorsal skin received a single UVB dose (200 mJ/cm2), was treated immediately, and was analyzed on Day 4. Drug-loaded MHA patch treatment attenuated UVB-induced epidermal thickening and was associated with qualitative differences in dermal matrix organization, while direct comparisons with the corresponding freely applied formulations varied across endpoints. These histological findings were evaluated using hematoxylin and eosin, Masson's trichrome, Picro-Sirius Red, and Fontana-Masson staining. GFP-loaded MHA hydrogels remained detectable in the epidermis and upper dermis through Day 4, supporting local cargo retention under skin-contact conditions. Preliminary HPLC-UV analysis detected arbutin and kojic acid parent peaks in MHA formulations before and after 60 s of UV exposure. Patch treatment was associated with significant reductions in α-smooth muscle actin and vimentin, whereas effects on SMAD phosphorylation differed between the two drug formulations, without detectable changes in body weight or serum TNF-α and IL-6. Because the main experiment lacked drug-free MHA patch and bandage-only controls, scaffold-, occlusion-, and drug-specific effects could not be fully separated. These findings support aligned nanofiber-supported MHA hydrogel arrays as functional biomaterial patches for localized cutaneous delivery and modulation of acute UVB-induced remodeling-associated responses.

PMID 42929246
阅读全文 →
PubMedClinics and practice2026-10-26

Destroyed Melanocytes Manifested with Poliosis and Halo Nevi in Children: Proposed Immunopathophysiological Mechanisms with Emphasis on Hair Follicle Immune Privilege.

Bulat Vedrana V, Paštar Zrinjka Z, Speeckaert Reinhart R, Marušić Dragana D et al.

Both poliosis (circumscribed depigmentation of the hair in any area of the body) and halo nevi (a melanocytic nevus which acquires a surrounding depigmented rim) are characterized by depigmentation driven by a T-cell-mediated loss of functional melanocytes within the epidermis and hair bulbs. Halo nevi and poliosis are a relatively frequent phenomenon occurring in 1% of the children and adolescents with an average age of onset of 15 years and has no gender predisposition. Both can be associated with vitiligo and are occasionally seen together as the same cytotoxic immune response (specifically CD8+ T cells) that destroys nevus melanocytes which can attack the same melanocyte-specific targets surrounding epidermal and follicular melanocytes. While poliosis is frequently seen on the scalp, halo nevi on the scalp have been scarcely reported in the literature. The timing of occurrence of the destruction of both epidermal and follicular melanocytes may be supported by a case of a 13-year-old Caucasian male with three halo nevi on the trunk which preceded the development of four scalp patches of poliosis. This may indicate that the halo nevi on the trunk induced a temporary systemic autoimmune reaction during the halo phenomenon, collaterally destroying melanocytes at distance on the scalp causing poliosis.

PMID 42930370
阅读全文 →
PubMedFood & function2026-10-26

Layered glycoprotein nanoparticles co-delivering Meretrix meretrix-derived peptide and astaxanthin attenuate cyclophosphamide-induced immunosuppression.

Wu Wanyi W, Cai Jiamin J, Wu Zhixuan Z, Cao Wenhong W et al.

Marked differences in solubility and stability between hydrophilic bioactive peptides and hydrophobic carotenoids constrain their synergistic oral delivery. Building on the complementary activities of Meretrix meretrix-derived immunomodulatory peptide (MMIP) and astaxanthin (AST), this study developed co-loaded nanoparticles, HLC10, featuring a BSA-dextran glycoprotein core and a composite outer layer of hyaluronic acid (HA) and yeast β-glucan. Hydrogen bonding, hydrophobic interactions, and electrostatic forces collectively drive the multicomponent assembly. By tuning particle interfacial hydration and the dispersion state of the payloads, the formulation improved co-encapsulation capacity, processing and storage stability, and gastrointestinal bioaccessibility of MMIP and AST. The composite polysaccharide outer layer further increased particle accumulation in Peyer's patches-associated regions and increased uptake by RAW264.7 macrophages. Oral HLC10 administration ameliorated cyclophosphamide-induced immunosuppression, restored immune organ and ileal architecture, and produced coordinated shifts in gut microbiota, fecal short-chain fatty acids, and spleen nucleotide-related metabolic profiles. These findings support the immunomodulatory potential of HLC10, but the evidence remains largely limited to endpoint measures in animal models, and direct validation of cellular functions and the underlying mechanisms is still required. Overall, this stratified co-assembly strategy offers a feasible route for the synergistic oral delivery of food-derived active ingredients with markedly different physicochemical properties.

PMID 42929794
阅读全文 →
PubMedBiosensors2026-10-26

HueFertility Ovulation: A Smartphone-Enabled Quantification System for Urinary Luteinizing Hormone in a Lateral Flow Assay.

Menon Nidhi N, Kara Erdi E, Sharma Prava P, Crutchfield Adrian A et al.

Luteinizing hormone (LH) is a critical biomarker for ovulation prediction and reproductive health monitoring, yet most commercially available at-home LH tests rely on qualitative or semi-quantitative visual interpretation, limiting their clinical utility. We present HueFertility Ovulation, a smartphone-enabled quantitative LH measurement system comprising a lateral flow immunoassay dipstick and a mobile application that integrates proprietary color correction algorithms with a deep learning regression model to deliver objective LH concentration estimates from strip images captured under variable real-world conditions. Color correction using the HueCard reference system substantially reduced inter-image color variability, decreasing mean ΔE00 from 11.19 to 4.02 across diverse lighting environments. When evaluated against known LH concentrations in a separately acquired independent dataset, the regression model achieved R2=0.92 and a mean absolute percentage error (MAPE) of 17.4%. The experimental limits of blank, detection, and quantitation were 0.64, 3.18, and 10.00 mIU/mL, respectively. Multi-site precision testing demonstrated %CVs within 25% across three independent locations. At a per-test cost of $0.60 with no external hardware required, HueFertility offers a low-cost, accessible platform for quantitative LH monitoring, with utility in fertility planning, hormonal health tracking, and resource-limited settings. Ultimately, the study highlights the opportunity to extend the technology to other low-cost lateral flow tests and clinical chemistry applications.

PMID 42930136
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

Buonerba Carlo C, Di Lorenzo Giuseppe G

Introducing [177Lu]Lu-PSMA-617 into metastatic hormone-sensitive prostate cancer (mHSPC) raises questions about patient selection and treatment sequencing. This non-systematic narrative review examines PSMAddition alongside evidence on alternative treatments, prostate-specific membrane antigen (PSMA) imaging, safety, and subsequent therapy. In the peer-reviewed analysis, with a data cutoff of 13 January 2025, adding radioligand therapy to androgen-deprivation therapy and an investigator-selected androgen receptor pathway inhibitor improved radiographic progression-free survival (hazard ratio 0.72; 95% confidence interval 0.58-0.90). Overall survival was immature and did not meet the prespecified interim significance threshold (hazard ratio 0.84; 95% confidence interval 0.63-1.13). A subsequent non-peer-reviewed sponsor update supported the radiographic findings, although the updated analysis was not controlled for type I error and overall survival remained immature. Radioligand intensification increased grade ≥3 adverse events (51% versus 43%). Prespecified composite quality-of-life and pain endpoints showed no statistically significant differences, although their interpretation is limited by the inclusion of progression or death. Control-arm crossover after progression was optional. Direct mHSPC evidence is distinguished from contextual castration-resistant evidence. Neither a preferred hormonal partner nor superiority over docetaxel-containing triplet therapy has been established. A non-prescriptive five-domain framework integrates target expression, disease characteristics, patient fitness, subsequent treatment options, and delivery capacity to support multidisciplinary assessment.

PMID 42930191
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hormone patches